by [150+ Pages Report] As per the latest Research and survey report issued by Precedence Research, the global anticoagulants market was valued at around USD 32 billion in 2021 and is expected to register revenues worth USD 70 billion by the end of 2030, growing at an exceptional CAGR of approximately 9.09% between 2022 and 2030.
Download Free Sample Copy with TOC@ https://www.precedenceresearch.com/sample/1796
Anticoagulants Market Report Scope
A recent study by Precedence Research on the anticoagulants market offers a forecast for 2022 and 2030. The study analyzes crucial trends that are currently determining the growth of the anticoagulants market. This report explicates on vital dynamics such as the drivers, restraints, and opportunities for key market players, along with key stakeholders as well as emerging players associated with the manufacturing of anticoagulants. The study also provides the dynamics that are responsible for influencing the future status of the anticoagulants market over the forecast period.
A detailed assessment of the anticoagulants market value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the anticoagulants market along with their product portfolio enhances the reliability of this comprehensive research study.
Competition Landscape
The report has engulfed a chapter on the global anticoagulants market’s competitive landscape, which provides detailed analysis and insights on companies offering anticoagulants. Profiles of key companies, along with a strategic overview of their M&A and expansion plans across geographies, have been delivered in this chapter. This chapter is priceless for report readers, as its enables them in gauging their growth potential in the market and implement key strategies for extending their market reach.
This chapter offers key recommendations for both new and existing market participants, enabling them to emerge sustainably and profitably. Intelligence on the market players has been delivered on the basis of their product overview, SWOT analysis, key developments, key financials and company overview. Occupancy of these market participants has been tracked by the report and portrayed via an intensity map.
Read Also@ Collagen Market Size to Worth Around US$ 20 Billion by 2030
Some of the Prominent Players in the Anticoagulants Market Include:
- Johnson & Johnson
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company
- Bayer AG
- Boehringer Ingelheim GmbH
- Aspen Holdings
- GlaxoSmithKline Plc
- Pfizer Inc.
- Sanofi S.A.
- Portola Pharmaceuticals
Anticoagulants Market Segmentation
By Indication of disease
- Pulmonary Embolism (PE)
- Deep Vein Thrombosis (DVT)
- Atrial Fibrillation
- Heart Attacks
- Others
By Administration Route
- Oral
- Injectable
By Drug Class
- NOACs
- Eliquis
- Bevyxxa
- Xarelto
- Savaysa & lixiana
- Pradaxa
- Heparin & LMWH
- Vitamin K Antagonist
- Others
By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacy
- Others
Regional Segmentation
- Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
- Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
- North America [United States, Canada, Mexico]
- South America [Brazil, Argentina, Columbia, Chile, Peru]
- Middle East & Africa [GCC, North Africa, South Africa]
Regional Analysis
The research report includes a detailed study of regions of North America, Europe, China, Japan and Rest of the World. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2022 to 2030. These analyses will help the reader to understand the potential worth of investment in a particular region.
The report provides in-depth segment analysis of the global anticoagulants market, thereby providing valuable insights at macro as well as micro levels. Analysis of major countries, which hold growth opportunities or account for significant share has also been included as part of geographic analysis of the anticoagulants market.
The report includes country-wise and region-wise market size for the period 2022-2030. It also includes market size and forecast by segments in terms of production capacity, price and revenue for the period 2022-2030.
Why should you invest in this report?
If you are aiming to enter the global anticoagulants market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for anticoagulants are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Anticoagulants Market
5.1. COVID-19 Landscape: Anticoagulants Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Anticoagulants Market, By Indication of disease
8.1. Anticoagulants Market, by Indication of disease, 2022-2030
8.1.1. Pulmonary Embolism (PE)
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Deep Vein Thrombosis (DVT)
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Atrial Fibrillation
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Heart Attacks
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Anticoagulants Market, By Administration Route
9.1. Anticoagulants Market, by Administration Route e, 2022-2030
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Injectable
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Anticoagulants Market, By Drug Class
10.1. Anticoagulants Market, by Drug Class, 2022-2030
10.1.1. NOACs
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Heparin & LMWH
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Vitamin K Antagonist
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Anticoagulants Market, By Distribution Channel
11.1. Anticoagulants Market, by Distribution Channel, 2022-2030
11.1.1. Hospitals Pharmacies
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Online Pharmacy
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Anticoagulants Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.1.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.1.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.2.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.2.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.3.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.3.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.4.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.4.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Indication of disease (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Administration Route (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 13. Company Profiles
13.1. Johnson & Johnson
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Bristol-Myers Squibb Company
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Daiichi Sankyo Company
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Bayer AG
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. BoehringerIngelheim GmbH
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Aspen Holdings
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. GlaxoSmithKline Plc
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Pfizer Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Sanofi S.A.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Portola Pharmaceuticals
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Buy This Premium Research Report Click Here@ https://www.precedenceresearch.com/checkout/1796
About Us
Precedence Research is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services we aim at connecting an organization’s goal with lucrative prospects globally.
From gauging investment feasibility to uncovering hidden growth opportunities, our market studies cover in-depth analysis, which also is interspersed with relevant statistics. Recommendation are often enclosed within our reports with the sole intent of enabling organizations achieve mission-critical success.
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
